ClinicalTrials.gg
RecruitingNCT04903262SUPERNOVAUpdated Apr 2, 2025

Ultra-Protective Lung Ventilation With Extracorporeal CO2 Removal for Moderate ARDS

An interventional study of Ultraprotective ventilation with Extracorporeal CO2 removal and Conventional protective ventilation in Acute Respiratory Distress Syndrome, sponsored by University of Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by University of Bologna · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in Respiratory Distress Syndrome with a site in Italy — 21 open to participants now, 24 under way, 2 of them phase 3. Respiratory Distress Syndrome · Italy.

Planned enrollment
13th of 49
230 · median 50
Started
2024
with 1 other
No phase
31 of 91
8 open now
Primary completion
2026-12
later than 11 of 23 live
Registered
59th of 91
by date

Among the 91 studies in Respiratory Distress Syndrome with a site in Italy, this one is the 13th largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2024, is one of 31 with no phase, reaches primary completion later than 11 of the 23 other live ones, and was the 59th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

21 of the 91 studies in Respiratory Distress Syndrome with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Respiratory Distress Syndrome with a site in Italy, or all of them as a file.
02

Study summary

Acute respiratory distress syndrome (ARDS) accounts for 10% of all ICU admissions and for 23% of patients requiring mechanical ventilation (MV). Its hospital mortality remains high, ranging from 34% in mild forms up to 46% in severe cases. Positive pressure MV remains the cornerstone of management, but at the same time it can contribute to worsening and maintenance of the lung injury when excessive stress and strain is applied to the lung parenchima (so-called ventilator-induced lung injury, VILI). VILI significantly contributes to the morbidity and mortality of ARDS patients, and it has been clearly demonstrated that protective (low-volume, low-pressure) MV settings are associated with a significant survival benefit. Unfortunately, in a certain proportion of ARDS cases, it is difficult to preserve acceptable gas exchange while maintaining protective ventilation settings, due to a high ventilatory load. In these cases, extracorporeal CO2 removal (ECCO2R) can be applied to grant the application of protective or even ultra-protective mechanical ventilation settings.

The main outcome of this multicenter, prospective, randomized, comparative open trial is to determine whether early ECCO2R allowing ultraprotective mechanical ventilation improves the outcomes of patients with moderate ARDS.

Read the detailed description

Acute respiratory distress syndrome (ARDS) represents a form of lung injury that occurs in response to various predisposing events, characterized by inflammation, increased pulmonary vascular permeability and loss of aerated lung tissue. The diagnosis of ARDS is based on severe hypoxemia and bilateral radiographic opacities occurring within 7 days of a known clinical insult or worsening respiratory symptoms. Central to the pathophysiology of ARDS is the presence of fibrin-rich exudates (hyaline membranes) due to activation of coagulation and inhibition of fibrinolysis. ARDS accounts for 10 % of all ICU admissions and for 23% of patients requiring mechanical ventilation (MV). Hospital mortality of ARDS patients remains high, ranging from 34% with mild ARDS, up to 46% with severe ARDS. Notably, severe and critical forms of coronavirus disease 2019 (COVID-19) are almost invariably associated with ARDS.

Ventilator Induced Lung Injury (VILI) MV is a lifesaving form of support for patients with ARDS since it decreases the oxygen cost of breathing, improves gas exchange and provides time for resolution of the underlying etiology of ARDS. However, it has been consistently shown that MV may contribute to ventilator-induced lung injury (VILI) characterized by progression of pulmonary damage, worsening of the pulmonary inflammatory process, increased alveolar-capillary permeability and therefore leading to the translocation of inflammatory mediators from the lungs into the systemic circulation with consequent failure of distal organs (biotrauma). A randomized clinical trial showed that ventilating ARDS patients with a tidal volume (VT) of 6 ml/kg (calculated from predicted body weight, PBW), and with a maximum end-inspiratory plateau pressure (PPLAT) of 30 cmH2O decreased mortality from 40 % (seen in the conventional arm treated with a VT of 12 ml/kg PBW) to 31%. Recently, Amato and coworkers showed that the delta pressure (∆P), i.e. the difference between PPLAT and positive end-expiratory pressure (PEEP) (∆P = PPLAT -PEEP) ≤ 14 cmH2O was strongly associated with survival, demonstrating that interventions to obtain protective ventilatory settings (reductions in VT or increases in PEEP) were beneficial only if associated with decreases in ΔP.

Extra-corporeal CO2 Removal (ECCO2-R) The use extracorporeal support to remove carbon dioxide (CO2) to permit the use of low volume/low pressure ventilation with minimal impact on PaCO2 was proposed in 1977. It was suggested that applying low VT and low peak inspiratory pressures ("lung rest") at a low respiratory rate could minimize damage to the compromised lungs. With this technique, oxygenation and removal of carbon dioxide were dissociated: oxygenation occurred predominantly through the lungs, and a variable portion of the carbon dioxide was removed through an artificial lung (extracorporeal CO2removal: ECCO2-R). The key potential advantage to this approach over extracorporeal membrane oxygenation (ECMO) is the use of lower blood flow through the extracorporeal circuit potentially with fewer side effects. Low VT ventilation (3-4 ml/kg of PBW) was associated with a significant decrease in inflammatory markers when compared with standard low volume, low pressure ventilation. Furthermore, the resulting hypercapnia was easily controlled by ECCO2-R. A randomized clinical trial showed that VT of 3 ml/kg of PBW was easy and safe to be implemented with extracorporeal CO2-removal. Clinical outcome, evaluated as days free from mechanical ventilation through day 28, significantly improved in ECCO2R patients compared to control, when analyzing patients with PaO2/FiO2\<150.

A multicenter study designed to assess safety and feasibility of ECCO2R in ARDS showed that more than 80% of patients with moderate ARDS could achieve ultra-protective ventilation goals by using ECCO2R. The incidence of severe adverse events related to ECCO2R was low (\~2%). Efficacy and safety of ECCO2R A was higher for devices that used blood flow rates in the range of 1000-1500 ml/min. A post-hoc analysis showed that restricting enrollment to patients with compliance of the respiratory system ≤ 40 ml/cmH2O and decrease in ∆P ≥ 5 cmH2O would increase predicted benefit in terms of clinical outcomes in a randomized clinical trial of VT of 3 ml/kg of PBW with ECCO2R (enrichment strategy). Moreover, recent data show that there is no safe upper limit for PPLAT or ΔP, consistent with the fact that since the mortality rate in ARDS patients with ΔP values ≤ 14 cmH2O is still as high as 20%. Patient outcomes may therefore be improved by aggressively lowering ventilatory variables such as VT, PPLAT, or ΔP as facilitated by ECCO2R devices that remove CO2. In addition, ECCO2R might further decrease VILI by allowing lower respiratory rates, which have been shown to be lung protective.

OBJECTIVE The objective of this multicenter, prospective, randomized, comparative open trial is to determine if early ECCO2R allowing ultraprotective mechanical ventilation (VT 4 ml/kg) improves the outcomes of patients with ARDS.

PROCEDURES

CONTROL GROUP

  • Patients will be treated with the following conventional ventilator settings ("standardized ventilation"): mode of mechanical ventilation: volume assist/control; VT = 6 mL/kg (PBW); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3; set RR to 20-35 bpm; PEEP will be set according to the "lower PEEP/FiO2" table:
  • PBW will be calculated according to the following formulae: PBW (Males) = 50 + 0.91 [height (cm)-152.4]; PBW (Females) = 45.5 + 0.91 height (cm)-152.4].
  • Oxygenation Goal: PaO2 55-80 mmHg or SpO2 88-95%;
  • Arterial pH Goal: 7.30-7.45.
  • It is recommended to perform 2 daily lung recruitment maneuvers (as per standard clinical practice in each center).
  • Patients may receive NMBA and continued as directed by the attending physician.
  • Use heated humidifiers for gas humidification and minimize instrumental dead space.

TREATMENT GROUP

  • Patients will be treated with the following conventional ventilator settings ("standardized ventilation"): mode of mechanical ventilation: constant flow, volume assist/control; VT = 6 mL/kg (PBW); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3; set RR to 20-35 bpm; PEEP will be set according to the "lower PEEP/FiO2" table:
  • PBW will be calculated according to the following formulae: PBW (Males) = 50 + 0.91 [height (cm)-152.4]; PBW (Females) = 45.5 + 0.91 height (cm)-152.4].
  • Oxygenation Goal: PaO2 55-80 mmHg or SpO2 88-95%;
  • Arterial pH Goal: 7.30-7.45.
  • Patients may receive NMBA and continued as directed by the attending physician.
  • Use heated humidifiers for gas humidification and minimize instrumental dead space.
  • ECCO2R will be initiated during "standardized ventilation".
  • Catheterization for ECCO2R will be performed according to local institutional clinical practice. The ECCO2R circuit will be connected to the catheter and blood flow set between 1000 and 1500 mL/min. Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device. Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0x baseline. A bolus of 80 I.U./kg unfractionated heparin is suggested at the time of cannulation.
  • The objective is to maintain PaCO2 at baseline value ± 20% of baseline settings obtained with a VT = 6 mL/kg provided that pH remains ≥ 7.30. End-tidal CO2 (EtCO2) will be monitored for safety purposes.
  • REDUCTION OF VT: Following a run-in time (up to a maximum of 2 hours) with sweep gas flow at zero LPM, VT will be reduced gradually to 5 mL/kg. Sweep gas will be initiated and VT decreased to 4.5 then 4 mL/kg, and PEEP adjusted to maintain the same mean airway pressure as during standardized ventilation, provided that Pplat ≤ 25 cmH2O (i.e., if the PEEP level required to maintain mean airway pressure leads to a Pplat > 25 cmH2O, PEEP is then reduced until a Pplat ≤ 25 cmH2O).
  • It is recommended to perform 2 daily lung recruitment maneuvers (as per standard clinical practice in each center).
  • REDUCTION OF RESPIRATORY RATE: Respiratory rate will be progressively decreased to a minimum of 8 bpm and facilitated by increases in sweep gas flow; a constant I:E ratio will be maintained.
  • If PaCO2 > 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
  • CO2 removal will be performed using the following device, routinely used for clinical purposes in each site:
  • HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator will be used, combined with HLS sets (BIOLINE heparine-coating). The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.

INTERRUPTION OF TREATMENT According to group assignment, "standardized ventilation" or "ultra protective ventilation + ECCO2R" will be maintained for at least 72 hours; then, interruption trials according to protocol will be performed every 24 hours, until liberation from mechanical ventilation and ECCO2R. In the treatment group, patients will be always weaned first from ECCO2R and subsequently from mechanical ventilation.

Interruption trials will be performed after at least 72 hours of study enrollment if all the following criteria are met: 1) PaO2/FiO2 > 250 with PEEP 8-10 cmH2O and FiO2 \<0.5; 2) values of both PEEP and FIO2 ≤ than values from previous day; 3) the patient is not receiving neuromuscular blocking agents; 4) the patient is exhibiting inspiratory efforts; 5) systolic arterial pressure ≥ 85 mmHg without vasopressor and/or inotropic support (≤ 5 mcg/kg/min dopamine or dobutamine will not be considered inotropic support in this context).

In the CONTROL group, in presence of all criteria 1-5, a spontaneous breathing trial will be conducted every 24 hours, until liberation from mechanical ventilation (see "weaning procedures" below).

In the TREATMENT group, in presence of all criteria 1-5, a zero-sweep gas trial will be conducted every 24 hours: sweep gas will be deactivated for 6 hours and then presence of all criteria 1-5 will be checked again; if still all present, ECCO2R will be removed and further weaning from mechanical ventilation will be conducted as in the control group.

RESCUE THERAPIES

  • Refractory hypoxemia will be defined as PaO2 \< 60 mm Hg for at least 1 hour while receiving an FIO2 of 1.0
  • Refractory acidosis will be defined as pH ≤ 7.10 for at least 1 hour
  • Refractory barotrauma will be defined as persistent pneumothorax with 2 chest tubes on the involved side or increasing subcutaneous or mediastinal emphysema with 2 chest tubes.

If refractory hypoxemia OR refractory acidosis OR refractory barotrauma occurs, the events surrounding this event(s) will be recorded and clinicians at their discretion may deviate from the assigned ventilation protocols and institute so-called rescue therapies, including: inhaled nitric oxide, prone position, extracorporeal membrane oxygenation (ECMO). The use of these therapies will be recorded in the study case report forms.

WEANING PROCEDURES

  • A Spontaneous Breathing Trial (SBT) procedure and assessment for unassisted breathing will be performed: 30 - 120 minutes of spontaneous breathing with FIO2 \< 0.5 using any of the following approaches: Pressure support (PS) \< 5 cmH2O, PEEP \< 5 cmH2O; CPAP \< 5 cmH2O; T-piece; Tracheotomy mask
  • Criteria to be met during the last 30 minutes of a SBT for reporting the SBT as "SUCCESSFUL": SpO2 ≥ 90% and / or PaO2 ≤ 60 mm Hg; Respiratory Rate ≤ 35 / min; pH ≥ 7.30; Absence of respiratory distress.
  • If any of the above-mentioned criteria is not met, the SBT will be reported as "UNSUCCESSFUL" and previous ventilator settings or to PS greater than or equal to 10 cm H2O with PEEP and FIO2 at the previous settings will be initiated. The patient will be reassessed for weaning the following day.
  • If the SBT is "SUCCESSFUL", ventilatory support will be removed.
  • Patients will be reported as "VENTILATOR FREE" after two consecutive calendar days of "UNASSISTED BREATHING". "UNASSISTED BREATHING" will be defined as any of the following: Spontaneously breathing with face mask, nasal prong oxygen, or room air; T-tube breathing; Tracheostomy mask breathing; CPAP ≤ 5 without PS or IMV assistance; use of CPAP or BIPAP solely for sleep apnea management
03

Conditions studied

  • Acute Respiratory Distress Syndrome
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • On invasive mechanical ventilation for ≤ 96 hours
  • Presence of all of the following conditions for ≤ 24 hours: 100 \< PaO2/FiO2 ≤ 200 after 12 hours of "standardized ventilation" with PEEP ≥ 5; compliance of the respiratory system ≤ 0.5 ml/cmH2O per kg PBW; ventilatory ratio (VR) ≥ 1.5; bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules; respiratory failure not fully explained by cardiac failure or fluid overload

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • ARDS with PaO2/FiO2\<100 or PaO2/FiO2>200 under standardized ventilation with PEEP ≥ 5 cmH2O
  • Expected duration of mechanical ventilation \< 48 hours
  • Severe
  • Chronic respiratory insufficiency with home ventilation or oxygen therapy
  • Currently receiving ECMO therapy
  • Acute brain injury
  • Severe liver insufficiency ( scores >7) or fulminant hepatic failure
  • Heparin-induced thrombocytopenia
  • for systemic anticoagulation
  • count \<50,000/mm3
  • -international normalized ratio (INR) >1.5
  • Patient moribund, decision to limit therapeutic interventions
  • End-stage disease
  • Unable to provide vascular access for ECCO2-R
  • Acute coronary syndrome
  • Actual body weight exceeding 1 kg per centimeter of height
  • Burns > 40% total body surface
  • Bone marrow transplantation within the last 1 year
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    ECCO2R

    Patients will be initially treated with "standardized ventilation": volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to "low PEEP/ high FiO2" table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45. ECCO2R initiated during "standardized ventilation" with blood flow between 1000 and 1500 mL/min. Anticoagulation with unfractionated heparin to a target aPTT of 1.5-2.0x baseline. Target: maintain PaCO2 at baseline ± 20%. VT initially reduced to 5 mL/kg. Sweep gas initiated and VT decreased to 4.5 then 4 mL/kg; PEEP adjusted to maintain same mean airway pressure as during "standardized ventilation", provided that Pplat ≤ 25 cmH2O. Respiratory rate decreased to 8 bpm. If PaCO2 \> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT. Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center).

    Procedure: Ultraprotective ventilation with Extracorporeal CO2 removal

  • Active comparator
    Standard of care

    Patients will be treated with "standardized ventilation": volume assist/control, VT = 6 mL/kg PBW; insp. flow 50-70 L/min, I:E ratio 1:1 to 1:3; RR 20-35 bpm; PEEP according to "low PEEP/ high FiO2" table. Goals: PaO2 55-80 mmHg or SpO2 88-95%; arterial pH: 7.30-7.45. Recommendation: 2 daily lung recruitment maneuvers (as per clinical practice in each center).

    Procedure: Conventional protective ventilation

Interventions

  • ProcedureUltraprotective ventilation with Extracorporeal CO2 removal

    HLS5.0 Cardiohelp® (Getinge Cardiopulmonary Care, Rastatt, Germany): 1.3 m² polymethylpentene hollow fiber membrane oxygenator. The extracorporeal blood flow is in the range of 1000 to 1500 mL/min. Sweep gas (air or oxygen) is drawn through the hollow fibers by a vacuum pump, creating a diffusion gradient for gas exchange across the membrane.

  • ProcedureConventional protective ventilation

    Conventional lung protective mechanical ventilation, as described in the arm description ("standardized ventilation")

06

What researchers measure

Primary outcomes

  1. Number of ventilator-free days (VFDs) at 28 days after randomization.

    VFD to-day 28 is defined as the number of days of unassisted breathing to day 28 after randomization, assuming a patient survives for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing.

    Time frame: 28 days

Secondary outcomes

  1. 28-day all-cause mortality

    All patients will be classified as either "alive at Study Day 28" or, if dead, "dead at Study Day 28."

    Time frame: 28 days

  2. 90-day all-cause mortality

    All patients will be classified as either "alive at Study Day 90" or, if dead, "dead at Study Day 90".

    Time frame: 90 days

  3. Cumulative incidence of severe adverse events during 28 days after randomization

    Device-related and/or patient-related severe adverse events

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 24 months is close to that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
May 26, 2021
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04903262
Collaborators
Getinge Group
Responsible party
V. Marco Ranieri (Full Professor, University of Bari Aldo Moro) — Principal investigator
First posted
May 26, 2021
Start date
Dec 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 2, 2025

Study contacts

Tommaso Tonetti, M.D.
Contact
tommaso.tonetti@unibo.it
+39-0512143268
Marco Ranieri, M.D.
Contact
m.ranieri@unibo.it
+39-0512143268
Marco Ranieri, M.D.
study chair · University of Bari
Antonio Pesenti, M.D.
study chair · University of Milan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion